DUBLIN, June 28, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Point of Care (PoC) Molecular Diagnostics Market Analysis By Application, By Technology, By Test Location, By End-use And Segment Forecasts To 2024" report to their offering.
Global point of care molecular diagnostics market is anticipated to reach USD 3.9 billion by 2024, according to this report. Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy & lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.
Growing demand for CLIA tests that are, by definition, portable and safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings, is expected to drive demand in the market over the forecast period. Ongoing research and development is continually supported and funded by a number of major international entities including the national governments of developed countries and high-value private funding agencies such as the Bill & Melinda Gates Foundation.
Furthermore, a growing portfolio of point-of-care testing capabilities that, had initially been focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties. Consequently, POC and molecular diagnosis tests are available and/or are under development for cardiology monitoring, oncology testing, and hematology testing.
Recent advances in the development of microfluidics and genetic sequencing instrumentation pave the way for development of cost-effective, highly accurate and rapid testing platforms, which are able to be used as true POC systems. This is a key factor that significantly contributes towards the favorably funded, high growth potential environment prevalent in the point of care molecular diagnostics market.
- Abbott Laboratories
- Alere Inc (Abbott)
- Bayer Healthcare
- Roche Diagnostics
- Bio-rad Laboratories
- Danaher Corporation
- Abaxis Inc.
- OraSure Technologies Inc.
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. Point of care Molecular Diagnostics Industry Outlook
4. Point of care Molecular Diagnostics Outlook, by Application
5. Point of care Molecular Diagnostics Outlook, by Technology
6. Point of care Molecular Diagnostics Outlook, by Test Location
7. Point of care Molecular Diagnostics Outlook, By End-use
8. Point of care Molecular Diagnostics Regional Outlook
9. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/gtfmzp/point_of_care
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/point-of-care-poc-molecular-diagnostics-market-worth-usd-39-billion-by-2024---growing-portfolio-of-point-of-care-testing-capabilities---research-and-markets-300291200.html
SOURCE Research and Markets